de Abajo F J, del Pozo J García, del Pino A
División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios, Ministerio de Sanidad y Consumo, Madrid, España.
Aten Primaria. 2005 Nov;36(8):424-33. doi: 10.1157/13081056.
To know the trends of supply, consumption and pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) in Spain from 1990 through 2003, as well as their costs.
Drug utilization study.
National Health System, outpatient setting.
Information on drug utilization was obtained from the ALHAQUEM database of the Spanish Ministry of Health, which contains the number of packages sold in community pharmacies and charged to the National Health System. Data were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DHD).
NSAIDs consumption in Spain increased from 23.67 DHD in 1990 to 45.82 DHD in 2003 (a 93.6% increase). Ibuprofen was the NSAID which showed the greatest increase (15.33 DHD in 2003). The consumption of coxibs reached a maximum of 7.74 DHD in 2001, but decreased to 3.59 DHD in 2003 once prior-authorization programs were set up. Over the study period the share of NSAIDs use with a low gastrointestinal risk increased from 29% to 59%. Overall costs of NSAIDs increased from 117 million euro in 1990 to 329 million euro in 2003.
Over the study period the consumption of NSAIDs in Spain has increased twofold while costs increased threefold. The pattern of use has remarkably changed showing an increasing use of NSAIDs with a better gastrointestinal profile. The impact of coxibs marketing has been moderate.
了解1990年至2003年西班牙非甾体抗炎药(NSAIDs)的供应、消费及使用模式趋势,以及其成本。
药物利用研究。
国家卫生系统,门诊环境。
药物利用信息来自西班牙卫生部的ALHAQUEM数据库,该数据库包含社区药房售出并计入国家卫生系统的药品包装数量。数据以每千居民每日限定日剂量(DDD)表示(DHD)。
西班牙NSAIDs的消费量从1990年的23.67 DHD增加到2003年的45.82 DHD(增长93.6%)。布洛芬是增长幅度最大的NSAID(2003年为15.33 DHD)。昔布类药物的消费量在2001年达到最高值7.74 DHD,但在2003年设立预先授权程序后降至3.59 DHD。在研究期间,胃肠道风险较低的NSAIDs使用比例从29%增加到59%。NSAIDs的总成本从1990年的1.17亿欧元增加到2003年的3.29亿欧元。
在研究期间,西班牙NSAIDs的消费量增加了两倍,而成本增加了三倍。使用模式发生了显著变化,胃肠道安全性更好的NSAIDs使用量增加。昔布类药物的市场影响较为温和。